Перейти к основному содержанию

Consortium Psychiatricum
2024. Том 5. № 3. С. 31–41
doi:10.17816/CP15525
ISSN: 2712-7672 / 2713-2919 (online)

Биологические методы диагностики депрессивных симптомов при шизофрении: нарративный обзор литературы

9

Султанова Р.И., Гашкаримов В.Р., Ефремов И.С., Асадуллин А.Р.

PDF (ENG)
GS
Информация
в Google Scholar

Аннотация

ВВЕДЕНИЕ: Депрессивная симптоматика при шизофрении приводит к более частым обострениям основного заболевания, ухудшению прогноза и повышению риска суицида. Перед клиницистами до сих пор стоит вопрос, связанный с трудностями диагностики этого расстройства.

ЦЕЛЬ: Произвести обзор литературы, направленный на поиск информации о биомаркерах депрессивных проявлений при шизофрении.

МЕТОДЫ: Поиск данных литературы осуществляли с применением следующих электронных сервисов для поиска публикаций (также указано общее число источников, обнаруженных по искомой теме): ACCESSSS (n=150), Cochrane Library (n=48), PubMed (n=623), eLIBRARY (n=216), Google Scholar (n=367). В итоговое обсуждение было включено 67 публикаций, соответствующих цели работы и опубликованных не ранее 01.01.2018 и не позднее 31.12.2023.

РЕЗУЛЬТАТЫ: При суммировании разрозненных данных предположено, что плазменные показатели (концентрация С-реактивного белка, метаболические, гормональные, ферментативные показатели, значения нейротрофических факторов) слабоспецифичны для диагностики депрессивных симптомов при шизофрении. С помощью методов нейровизуализации установлено, что уменьшение объема серого вещества в теменной, лобной и височной доле (особенно в зонах Брока и Вернике), а также в префронтальной коре — в медиальной части правой верхней лобной, медиальной орбитофронтальной, верхней и средней фронтальных извилины — связано с депрессивными проявлениями. Предполагается связь между генами SIRT1, OXT, CDKAL1 и APOE в возникновении депрессивных симптомов у пациентов с шизофренией.

ЗАКЛЮЧЕНИЕ: Понимание и выявление депрессивных симптомов при шизофрении позволит улучшить качество помощи, получаемой пациентами с этим расстройством.

Общая информация

Ключевые слова: симптомы депрессии, шизофрения, нейробиология

Рубрика издания: Обзоры

Тип материала: научная статья

DOI: https://doi.org/10.17816/CP15525

Получена: 26.03.2024

Принята в печать:

Для цитаты: Султанова Р.И., Гашкаримов В.Р., Ефремов И.С., Асадуллин А.Р. Биологические методы диагностики депрессивных симптомов при шизофрении: нарративный обзор литературы // Consortium Psychiatricum. 2024. Том 5. № 3. С. 31–41. DOI: 10.17816/CP15525

Литература

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington: American Psychiatric Publishing; 2013. 947 p. doi: 10.1176/appi.books.9780890425596
  2. Bleuler E. Dementia praecox, oder Gruppe der Schizophrenien. Leipzig und Vienna: F. Deuticke; 1911. 420 S.
  3. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research ICD-10. Geneva: World Health Organization; 1993. 248 p.
  4. Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull. 2017;43(2):240–244. doi: 10.1093/schbul/sbw097
  5. Mosolov SN. Diagnosis and treatment depression in schizophrenia. Consort Psychiatr. 2020;1(2):29–42. doi: 10.17816/CP29-42
  6. Bassett AS, Bury A, Honer WG. Testing Liddle’s three-syndrome model in families with schizophrenia. Schizophr Res. 1994;12(3):213–221. doi: 10.1016/0920-9964(94)90031-0
  7. Mosolov SN, Malyutin AV, Pikalov AA. [Effect of Lurasidone on symptoms of schizophrenia in five-factor dimensional model: pooled analysis of two short-term, randomized, double-blind, placebo-controlled studies in patients from Russia and Ukraine]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(12):29–37. Russian. doi: 10.17116/jnevro201911912129
  8. ICD-11 for mortality and morbidity statistics [Internet]. 2018 [cited 2022 Jul 25]. Available from: https://icd.who.int/browse/2018/mms/en
  9. Pavlichenko AV, Kulygina MA, Kostyuk GP. [Schizophrenia and other psychotic disorders in ICD-11 and DSM-5: evolution of the concepts and current status]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2020;120(6 Iss. 2):5–12. Russian.
  10. Liu J, Chan TCT, Chong SA, et al. Impact of emotion dysregulation and cognitive insight on psychotic and depressive symptoms during the early course of schizophrenia spectrum disorders. Early Interv Psychiatry. 2020;14(6):691–697. doi: 10.1111/eip.12895
  11. Kim M, Lee Y, Kang H. Effects of Exercise on Positive Symptoms, Negative Symptoms, and Depression in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2023;20(4):3719. doi: 10.3390/ijerph20043719
  12. Novitskiy MA, Shnayder NA, Bugay VA, et al. [Use of parametric methods and questionnaires for the study of depressive and anxiety disorders in schizophrenia]. Doctor.Ru. 2021;20(5):55–61. Russian. doi: 10.31550/1727-2378-2021-20-5-55-61
  13. Siris SG, Braga RJ. Depression in schizophrenia [Internet]. 2023 [cited 2024 Jul 12]. Available from: https://medilib.ir/uptodate/show/14791
  14. Mazoм GE, Ganzenko MA, Rukavishnikov GV, et al. [Depression in schizophrenia: approaches to therapy: methodological recommendations]. Saint Petersburg: V. M. Bekhterev National Medical Research Center of Psychiatry and Neurology; 2020. 22 p. Russian.
  15. Andira S, Nuralita NS. [Influence of Sexual Differences on Depressive Symptom of Schizophrenia Patients in Rumah Sakit Jiwa Prof. Dr. M. Ildrem Medan North Sumatra 2017]. Buletin Farmatera. 2018;3(2):97–108. Indonesian.
  16. Häfner H. From onset and prodromal stage to a life-long course of schizophrenia and its symptom dimensions: how sex, age, and other risk factors influence incidence and course of illness. Psychiatry J. 2019;9804836. doi: 10.1155/2019/9804836
  17. Wang TT, Beckstead JW, Yang CY. Social interaction skills and depressive symptoms in people diagnosed with schizophrenia: The mediating role of auditory hallucinations. Int J Ment Health Nurs. 2019;28(6):1318–1327. doi: 10.1111/inm.12643
  18. McGinty J, Haque MS, Upthegrove R. Depression during first episode psychosis and subsequent suicide risk: a systematic review and meta-analysis. Schizophr Res. 2018;195:58–66. doi: 10.1016/j.schres.2017.09.040
  19. Vauth R, Carpiniello B, Turczyński J, et al. Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia. Int J Methods Psychiatr Res. 2021;30(2):e1855. doi: 10.1002/mpr.1855
  20. Rostami R, Kazemi R, Khodaie-Ardakani MR, et al. The Persian version of the Calgary depression scale for schizophrenia (CDSS-P). Asian J Psychiatry. 2019;45:44–49. doi: 10.1016/j.ajp.2019.08.017
  21. Hettige NC, Bani-Fatemi A, Sakinofsky I, et al. A biopsychosocial evaluation of the risk for suicide in schizophrenia. CNS Spectr. 2018;23(4):253–263. doi: 10.1017/S1092852917000128
  22. Sher L, Kahn RS. Suicide in schizophrenia: an educational overview. Medicina (Kaunas). 2019;55(7):361. doi: 10.3390/medicina55070361
  23. Simon GE, Stewart C, Yarborough BJ, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiatry. 2018;75(3):254–260. doi: 10.1001/jamapsychiatry.2017.4437
  24. Schwarz E, Guest P, Rahmoune H et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17. (2012);494–502. doi: 10.1038/mp.2011.42
  25. Stoeber G, Opler LA, Reis HJ, Schmitt A, Convit A, Lawrie SM, et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry. 2009;10(2):127-55. doi: 10.1080/15622970802573031
  26. DiCenso A, Bayley L, Haynes RB. Accessing pre-appraised evidence: fine-tuning the 5S model into a 6S model. Evid Based Nurs. 2009;12(4):99–101. doi: 10.1136/ebn.12.4.99
  27. Faugere M, Micoulaud-Franchi JA, Faget-Agius C, et al. High C-reactive protein levels are associated with depressive symptoms in schizophrenia. J Affect Disord. 2018;225:671–675. doi: 10.1016/j.jad.2017.08.071
  28. Fang X, Chen L, Wang D, et al. Metabolic profiling identifies TC and LDL as potential serum biomarkers for depressive symptoms in schizophrenia. Psychiatry Res. 2019;281:112522. doi: 10.1016/j.psychres.2019.112522
  29. Xu J, Jiao Y, Xing M, et al. Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia. Gen Psychiatr. 2018;31(3):e100018. doi: 10.1136/gpsych-2018-100018
  30. Kumar P, Kraal AZ, Prawdzik AM, et al. Dietary glutamic acid, obesity, and depressive symptoms in patients with schizophrenia. Front Psychiatry, 2021;11:620097. doi: 10.3389/fpsyt.2020.620097
  31. Miller BJ, McEvoy JP, McCall WV, et al. Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia. Shizophr Res. 2022;250:134–136. doi: 10.1016/j.schres.2022.11.01
  32. Lang XE, Zhang H, Wang N, et al. Elevated activity of plasma superoxide dismutase in never-treated first-episode schizophrenia patients: Associated with depressive symptoms. Schizophr Res. 2020;222:291–296. doi: 10.1016/j.schres.2020.05.032
  33. Bigseth TT, Engh JA, Egeland J, et al. Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms. BMC Psychiatry. 2021;21(1):527. doi: 10.1186/s12888-021-03522-6
  34. Peng S, Li W, Lv L, et al. BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression. Discov Med. 2018;26(143):127–136.
  35. Manchia M, Isayeva U, Collu R, et al. Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders. Brain Sci. 2022;12(12):1666. doi: 10.3390/brainsci12121666
  36. Wu Y, Du X, Yang R, et al. Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients with First-Episode and Drug-Naïve Schizophrenia. Front Psychiatry. 2022;13:911384. doi: 10.3389/fpsyt.2022.911384
  37. Han D, Sun D, Xiu M, et al. Association between the improvement in depressive symptoms and serum BDNF levels in drug-naive first episode patients with schizophrenia: a longitudinal follow-up. Psychoneuroendocrinology. 20214; 133:105392. doi: 10.1016/j.psyneuen.2021.105392
  38. Arabska J, Łucka A, Strzelecki D, et al. In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present. Neurosci Lett. 2018;684:152–155. doi: 10.1016/j.neulet.2018.08.005
  39. van Erp TGM, Walton E, Hibar DP, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. Biol Psychiatry. 2018;84(9):644–654. doi: 10.1016/j.biopsych.2018.04.023
  40. Gray JP, Müller VI, Eickhoff SB, et al. Multimodal abnormalities of brain structure and function in major depressive disorder: a meta-analysis of neuroimaging studies. Am J Psychiatry. 2020;177(5):422–434. doi: 10.1176/appi.ajp.2019.19050560
  41. Siddi S, Nuñez C, Senior C, et al. Depression, auditory-verbal hallucinations, and delusions in patients with schizophrenia: Different patterns of association with prefrontal gray and white matter volume. Psychiatry Res Neuroimaging. 2019;283:55–63. doi: 10.1016/j.pscychresns.2018.12.001
  42. Wei GX, Ge L, Chen LZ, et al. Structural abnormalities of cingulate cortex in patients with first-episode drug-naïve schizophrenia comorbid with depressive symptoms. Hum Brain Mapp. 2021;42(6):1617–1625. doi: 10.1002/hbm.25315
  43. Zhuo C, Fang T, Chen C, et al. Brain imaging features in schizophrenia with co-occurring auditory verbal hallucinations and depressive symptoms – Implication for novel therapeutic strategies to alleviate the reciprocal deterioration. Brain Behav. 2021;11(2):e01991. doi: 10.1002/brb3.1991
  44. Ji F, Chen C, Chen M, et al. Brain impairment in chronic schizophrenia patients with depressive symptoms differs from brain impairment in chronic depression patients with psychotic symptoms. Chin Med J (Engl). 2018;131(5):620–621. doi: 10.4103/0366-6999.226060
  45. Shor O, Yaniv-Rosenfeld A, Valevski A, et al. EEG-based spatio-temporal relation signatures for the diagnosis of depression and schizophrenia. Sci Rep. 2023;13(1):776. doi: 10.1038/s41598-023-28009-0
  46. Liu J, Zheng L, Fang T, et al. Exploration of the cortical pathophysiology underlying visual disturbances in schizophrenia comorbid with depressive disorder — An evidence from mouse model. Brain Behav. 2021;11(5):e02113. doi: 10.1002/brb3.2113
  47. Zhou C, Kong D, Zhu X, et al. Rethinking schizophrenia and depression comorbidity as one psychiatric disorder entity: evidence from mouse model. Front Neurosci. 2020;14:115. doi: 10.3389/fnins.2020.00115
  48. Wan L, Li Y, Zhang Z, et al. Methylenetetrahydrofolate reductase and psychiatric diseases. Transl Psychiatry. 2018;8(1):242. doi: 10.1038/s41398-018-0276-6
  49. Zhang Y, Zhao J, Wang W, et al. Homocysteine, but not MTHFR gene polymorphism, influences depressive symptoms in patients with schizophrenia. J Affect Disord. 2020;272:24–27. doi: 10.1016/j.jad.2020.03.121
  50. Fang X, Chen Y, Wang Y, et al. Depressive symptoms in schizophrenia patients: a possible relationship between SIRT1 and BDNF. Prog Neuropsychopharmacol Biol Psychiatry. 2019;95:109673. doi: 10.1016/j.pnpbp.2019.109673
  51. Shkundin A, Halaris A. Associations of BDNF/BDNF-AS SNPs with depression, schizophrenia, and bipolar disorder. J Pers Med. 2023;13(9):1395. doi: 10.3390/jpm13091395
  52. Lu G, Li J, Zhang H, et al. Role and possible mechanisms of Sirt1 in depression. Oxid Med Cell Longev. 2018;2018:8596903. doi: 10.1155/2018/8596903
  53. Wang D, Tang W, Zhao J, et al. A comprehensive analysis of the effect of SIRT1 variation on the risk of schizophrenia and depressive symptoms. Front Genet. 2020;11:832. doi: 10.3389/fgene.2020.00832
  54. Broniarczyk-Czarniak M, Szemraj J, Śmigielski J, et al. The role of OXT, OXTR, AVP, and AVPR1a gene expression in the course of schizophrenia. Curr Issues Mol Biol. 2022;44(1):336–349. doi: 10.3390/cimb44010025
  55. Hughes ZH, Hughes LM, Khan SS. Genetic contributions to risk of adverse pregnancy outcomes. Curr Cardiovasc Risk Rep. 2023;17(11):185–193. doi: 10.1007/s12170-023-00729-y
  56. Li W. Association of APOE E2 and low-density lipoprotein with depressive symptoms in Chinese senile schizophrenia inpatients: A cross-sectional study. Schizophr Res Cogn. 2020;23:100193. doi: 10.1016/j.scog.2020.100193
  57. Krynicki CR, Upthegrove R, Deakin JFW, et al. The relationship between negative symptoms and depression in schizophrenia: A systematic review. Acta Psychiatr Scand. 2018;137(5):380–390. doi: 10.1111/acps.12873
  58. Lalousis PA, Schmaal L, Wood SJ, et al. Neurobiologically based stratification of recent-onset depression and psychosis: identification of two distinct transdiagnostic phenotypes. Biol Psychiatry. 2022;92(7):552–562. doi: 10.1016/j.biopsych.2022.03.021
  59. Ruderfer DM, Ripke S, McQuillin A, et al. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell. 2018;173(7):1705–1715.e16. doi: 10.1016/j.cell.2018.05.046
  60. van Rooijen G, Vermeulen JM, Ruhé HG, et al. Treating depressive episodes or symptoms in patients with schizophrenia. CNS Spectr. 2019;24(2):239–248. doi: 10.1017/S1092852917000554
  61. Naguy A. Depression in schizophrenia – A good or bad omen? Asia Pac Psychiatry. 2018;10(2):e12312. doi: 10.1111/appy.12312
  62. Mosolov SN, Tsukarzi EE. Psychopharmacotherapy of schizophrenia. In: Psihiatriya: nacional’noe rukovodstvo. Moscow: GEOTAR-Media; 2021. p. 252–278. Russian.
  63. Maslenikov NE, Tsukarzi EE, Mosolov SN. [Algorithm of biological treatment for depression in schizophrenia]. Sovremennaja terapija psihicheskih rasstrojstv. 2019;(1):31–40. Russian. doi: 10.21265/PSYPH.2019.34.92.005
  64. Edwards CJ, Garety P, Hardy A. The relationship between depressive symptoms and negative symptoms in people with non-affective psychosis: a meta-analysis. Psychol Med. 2019;49(15):2486–2498. doi: 10.1017/S0033291719002381
  65. Guessoum SB, Le Strat Y, Dubertret C, et al. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109862. doi: 10.1016/j.pnpbp.2020.109862
  66. Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534. doi: 10.2147/NDT.S225643
  67. Demyttenaere K, Anthonis E, Correll CU. Depressive symptoms and PANSS symptom dimensions in patients with predominant negative symptom schizophrenia: a network analysis. Front Psychiatry. 2022;13:795866. doi: 10.3389/fpsyt.2022.795866

Информация об авторах

Султанова Рената Ильдаровна, Врач-психиатр, ГБУЗ «Научно-практический психоневрологический центр имени З.П. Соловьева» Департамента здравоохранения города Москвы , Москва, Россия, ORCID: https://orcid.org/0000-0001-6679-4454, e-mail: renatasu@mail.ru

Гашкаримов Вадим Римович, Врач-психиатр, ГБУЗ «Республиканская клиническая психиатрическая больница» Минздрава Республики Башкортостан, Уфа, Россия, ORCID: https://orcid.org/0000-0001-9944-141X, e-mail: gashkarimov@yandex.ru

Ефремов Илья Сергеевич, кандидат медицинских наук, Ассистент кафедры психиатрии, наркологии и психотерапии с курсами ИДПО, ФГБОУ ВО «Башкирский Государственный Медицинский Университет» Минздрава России, Младший научный сотрудник, ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России, Уфа, Россия, ORCID: https://orcid.org/0000-0002-9994-8656, e-mail: efremovilya102@gmail.com

Асадуллин Азат Раилевич, доктор медицинских наук, Профессор кафедры психиатрии, наркологии и психотерапии с курсами ИДПО, ФГБОУ ВО «Башкирский Государственный Медицинский Университет» Минздрава России, Ведущий научный сотрудник ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России; Заместитель главного врача по медицинской части, ГБУЗ «Республиканский клинический психотерапевтический центр» Минздрава Республики Башкортостан, Уфа, Россия, ORCID: https://orcid.org/0000-0001-7148-4485, e-mail: droar@yandex.ru

Метрики

Просмотров

Всего: 36
В прошлом месяце: 22
В текущем месяце: 14

Скачиваний

Всего: 9
В прошлом месяце: 6
В текущем месяце: 3